Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ablynx NV

Division of Sanofi
www.ablynx.com

Latest From Ablynx NV

Purple Patch For Pharma/Biotech R&D As NAS Launches Reach Record High

The pharma and biotech industries enjoyed their most productive year since the turn of the century in terms of number of novel products launched worldwide in 2018.

Launches Analysis

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Mentioned In Despatches: Ablynx's Story From The Frontline Of The Biotech Boom

A little over 12 months ago, Belgian Nanobody biotech Ablynx was at the center of a bidding war between Novo Nordisk and Sanofi. Ex-Ablynx CEO Edwin Moses talked to Scrip about the four-month period that changed the course of the company.

M & A Leadership

Q4 Pharma Earnings Preview: GSK, Lilly, Sanofi And AstraZeneca

GlaxoSmithKline will update investors on strategy after completing its Tesaro acquisition. Lilly may have guidance updates following its Loxo acquisition and Lartruvo setback news. Sanofi investors await a pair of new approvals, and AstraZeneca faces investors for the first time since the departure of Chief Medical Officer Sean Bohen and establishing a new organizational structure.

Sales & Earnings Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Edwin Moses, PhD, CEO
    Wim Ottevaere, CFO
    Markus Ewert, PhD, CBO
    Robert K Zeldin, MD, CMO
    Heylen Johan, Chief Commerical Officer
    Robert Friesen, PhD, CSO
  • Contact Info
  • Ablynx NV
    Phone: (32) 9 262 00 00
    Technologiepark 21
    Ghent/Zwijnaarde, 9052
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register